>Mercado de tratamento de cólicas menstruais da América do Norte, por tipo (dismenorreia primária, dismenorreia secundária), tipo de tratamento (medicamento, terapia, cirurgia, outros), modo de prescrição (sem receita médica, receita médica), via de administração (oral, parentérica, implantes, Outros), Utilizador final (hospitais, centros especializados, centros de cirurgia ambulatória, outros), canal de distribuição (farmácias, vendas a retalho, concurso direto, outros), país (EUA, Canadá, México) Tendências e previsões da indústria para 2028
Análise de mercado e insights: Mercado de tratamento de cólicas menstruais da América do Norte
Espera-se que o mercado de tratamento de cólicas menstruais ganhe crescimento de mercado no período de previsão de 2021 a 2028. A Data Bridge Market Research analisa que o mercado está a crescer com um CAGR de 7,6% no período de previsão de 2021 a 2028 e prevê-se que atinja os 3.335,97 milhões de USD até 2028. O aumento da prevalência de doenças de saúde menstrual, como as cólicas menstruais, e a extensa atividade de investigação e desenvolvimento no tratamento das cólicas menstruais são os principais impulsionadores que impulsionaram a procura do mercado no período de previsão.
As cólicas menstruais são cólicas e dores pulsáteis na parte inferior do abdómen do corpo. Muitas mulheres têm cólicas menstruais antes e depois dos períodos menstruais. Para algumas mulheres, as cólicas menstruais são comuns, enquanto que para outras mulheres as cólicas menstruais são incómodas e bastante graves, o que interfere com as atividades diárias durante alguns dias de cada mês. Os sintomas das cólicas menstruais são dores que começam 1 a 3 dias antes da menstruação, atingem o pico 24 horas após o início da menstruação e diminuem em 2 a 3 dias juntamente com embotamento, dor contínua, náuseas, dor de cabeça , tonturas, fezes moles e outros.
O tratamento das cólicas menstruais compreende características como a crescente necessidade de um tratamento eficaz para as cólicas menstruais que terá impacto no lançamento de novos produtos pelos fabricantes no mercado, o que aumenta a sua procura, bem como o aumento das iniciativas governamentais e das indústrias farmacêuticas leva à crescimento do mercado de tratamento das cólicas menstruais. O uso de terapias alternativas atua como um desafio para o crescimento do mercado de tratamento das cólicas menstruais.
Estão actualmente em curso programas de sensibilização que deverão criar uma vantagem competitiva para os fabricantes desenvolverem tecnologias novas e inovadoras. Além disso, espera-se também que estes programas de sensibilização proporcionem várias outras oportunidades no mercado de tratamento das cólicas menstruais. No entanto, espera-se que a presença das terapias tradicionais restrinja o crescimento do mercado de tratamento das cólicas menstruais no período de previsão.
O relatório de mercado de tratamento de cólicas menstruais fornece detalhes de quota de mercado, novos desenvolvimentos e análise de pipeline de produtos, impacto dos participantes do mercado doméstico e localizado, analisa oportunidades em termos de bolsas de receitas emergentes, mudanças nas regulamentações de mercado, aprovações de produtos, decisões estratégicas, lançamentos de produtos , expansões geográficas e inovações tecnológicas no mercado. Para compreender a análise e o cenário do mercado de tratamento de cólicas menstruais, contacte a Data Ridge Market Research para obter um resumo do analista, a nossa equipa irá ajudá-lo a criar uma solução de impacto na receita para atingir o objetivo desejado.
Âmbito do mercado de tratamento de cólicas menstruais da América do Norte e dimensão do mercado
O mercado de tratamento das cólicas menstruais está segmentado com base no tipo, tipo de tratamento, modo de prescrição, via de administração, utilizador final e canal de distribuição. O crescimento entre segmentos ajuda-o a analisar os nichos de crescimento e as estratégias para abordar o mercado e determinar as suas principais áreas de aplicação e a diferença nos seus mercados-alvo.
- Com base no tipo, o mercado de tratamento das cólicas menstruais está segmentado em dismenorreia primária e dismenorreia secundária. Em 2021, o segmento da dismenorreia primária está a dominar o mercado do tratamento das cólicas menstruais, uma vez que 85% das mulheres nos Estados Unidos da América sofrem ou enfrentam cólicas menstruais durante a menstruação.
- Com base no tipo de tratamento, o mercado de tratamento das cólicas menstruais está segmentado em medicamentos , terapia, cirurgia e outros. Em 2021, o segmento dos medicamentos está a dominar o mercado do tratamento das cólicas menstruais devido aos medicamentos anti-inflamatórios não esteróides e contracetivos orais combinados que representam a terapêutica de primeira linha para a dor da dismenorreia.
- Com base no modo de prescrição, o mercado de tratamento das cólicas menstruais está segmentado em prescrição e venda livre. Em 2021, o segmento de venda livre está a dominar o mercado de tratamento de cólicas menstruais devido à maior parte dos medicamentos estarem disponíveis genéricos e fornecimento de produtos farmacêuticos sem qualquer impedimento e sensibilizando as massas pelas virtudes da publicidade.
- Com base na via de administração, o mercado de tratamento das cólicas menstruais está segmentado em oral, parentérica , implantes e outros. Em 2021, o segmento oral está a dominar o mercado de tratamento das cólicas menstruais devido ao segmento oral ser considerado a primeira linha de tratamento. Além disso, a medicação oral tem uma melhor adesão por parte do doente, o que serve como outro fator determinante.
- Com base no utilizador final, o mercado de tratamento das cólicas menstruais está segmentado em hospitais , centros de cirurgia ambulatória, centros especializados e outros. Em 2021, o segmento hospitalar está a dominar o mercado do tratamento das cólicas menstruais porque a maioria das doentes apresenta sintomas da menopausa, pelo que seriam vistas no hospital para obter um diagnóstico e tratamento adequados.
- On the basis of distribution channel, the menstrual cramps treatment market is segmented into direct tender, retail sales, pharmacies and others. In 2021, pharmacies segment is dominating the menstrual cramps treatment market as variety of medicines available in the pharmacies according to the patient need and demand.
Menstrual Cramps Treatment Market Country Level Analysis
The menstrual cramps treatment market is analysed and market size information is provided by the country, type, treatment type, mode of prescription, route of administration, end user and distribution channel as referenced above.
The countries covered in the North America menstrual cramps treatment market report are the U.S., Canada, and Mexico.
Mode of prescription segment in North America is expected to dominate the market due to the high adoption of OTC menstrual cramps treatment by the patients in the region. The U.S is dominating in the market and leading the growth in the North America due to increased presence of key market players in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Increasing Number of Treatment Options in Menstrual Cramps Treatment Market is Creating New Opportunities for Players in the Market
Menstrual cramps treatment market also provides you with detailed market analysis for every country growth in aesthetic industry with menstrual cramps treatment sales, impact of advancement in the menstrual cramps treatment and changes in regulatory scenarios with their support for the menstrual cramps treatment market. The data is available for historic period 2010 to 2019.
Competitive Landscape and Menstrual Cramps Treatment Market Share Analysis
Menstrual cramps treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to menstrual cramps treatment market.
As principais empresas que se ocupam do tratamento das cólicas menstruais são a Bayer AG, a GlaxoSmithKline plc, a Pfizer Inc., a Teva Pharmaceuticals USA, Inc. (uma subsidiária da Teva Pharmaceutical Industries Ltd.), a Beurer GmbH, a Mylan NV (uma parte da Viatris Inc . .), Boehringer Ingelheim International GmbH, PMS4PMS, LLC, Sanofi, Nobelpharma Co., Ltd., ObsEva, Myovant Sciences Ltd., AbbVie Inc., BioElectronics Corporation, Alvogen, Cumberland Pharmaceuticals Inc., Lupin Pharmaceuticals, Inc. da LUPIN ), Janssen Pharmaceuticals, Inc. (uma subsidiária da Johnson & Johnson Services, Inc.), Sun Pharmaceutical Industries Ltd., entre outros players nacionais e globais. Os analistas DBMR compreendem os pontos fortes competitivos e fornecem análises competitivas para cada concorrente em separado.
Muitos lançamentos e acordos de produtos são também iniciados pelas empresas de todo o mundo, que também estão a acelerar o mercado de tratamento das cólicas menstruais.
Por exemplo,
- Em maio de 2019, a PMS4PMS, LLC anuncia o lançamento do produto denominado Comforte. O produto proporciona alívio das cólicas menstruais durante o ciclo menstrual. Este novo produto lançado pela empresa aumentou a sua procura e vendas no mercado.
A colaboração, as joint ventures e outras estratégias dos participantes do mercado estão a melhorar o mercado empresarial no mercado de tratamento de cólicas menstruais, o que também oferece o benefício para a organização melhorar a sua oferta de tratamento de cólicas menstruais.
SKU-
Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo
- Painel interativo de análise de dados
- Painel de análise da empresa para oportunidades de elevado potencial de crescimento
- Acesso de analista de pesquisa para personalização e customização. consultas
- Análise da concorrência com painel interativo
- Últimas notícias, atualizações e atualizações Análise de tendências
- Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Índice
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 SECONDARY SOURCES
2.11 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PIPELINE ANALYSIS
4.1 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, PIPELINE ANALYSIS
5 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: REGULATIONS
6 PREMIUM INSIGHTS
6.1 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: ADOPTION RATE
6.1.1 DRIVERS AND BARRIERS FOR THE ADOPTIONS
6.2 MARKETING EXPENSES
6.3 PAYERS:
6.4 PHARMACIES COLD/HOT PADS MARKET SHARE:
7 EPIDEMIOLOGY
8 COVID-19 IMPACT ON NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET
8.1 PRICE IMPACT
8.2 IMPACT ON DEMAND
8.3 IMPACT ON SUPPLY CHAIN
8.4 STRATEGIC INITIATIVES BY MARKET PLAYERS DURING COVID-19
8.5 CONCLUSION
9 MARKET OVERVIEW
9.1 DRIVERS
9.1.1 GROWING PREVALENCE OF DYSMENORRHEA
9.1.2 RISING TECHNOLOGICAL ADVANCEMENTS
9.1.3 INCREASING RESEARCH AND DEVELOPMENT FOR DEVELOPING INNOVATIVE DRUGS AND THERAPIES
9.1.4 GOVERNMENT INITIATIVES WITH RESPECT TO WOMEN HEALTHCARE
9.1.5 INCREASING NUMBER OF TREATMENT OPTIONS
9.2 RESTRAINTS
9.2.1 PRODUCT RECALLS
9.2.2 LACK OF AWARENESS ABOUT REPRODUCTIVE HEALTH IN WOMEN
9.2.3 HIGH COST OF ENDOMETRIAL ABLATION AND HYSTERECTOMY
9.3 OPPORTUNITIES
9.3.1 RISE IN AWARENESS ABOUT DYSMENORRHEA
9.3.2 STRATEGIC INITIATIVES BY KEY MARKET PLAYERS
9.3.3 RISING DISPOSABLE INCOME
9.4 CHALLENGES
9.4.1 TRADITIONAL FAMILY VALUE LEADING TO NO TREATMENT
9.4.2 SIDE EFFECTS AND COMPLICATIONS ASSOCIATED WITH LONG TERM TREATMENT
9.4.3 EFFECTIVENESS OF COMPLEMENTARY AND ALTERNATIVE THERAPIES
10 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE
10.1 OVERVIEW
10.2 PRIMARY DYSMENORRHEA
10.3 SECONDARY DYSMENORRHEA
11 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE
11.1 OVERVIEW
11.2 MEDICATION
11.2.1 FIRST LINE TREATMENT
11.2.1.1 Nonhormonal Therapy
11.2.1.1.1 Nonsteroidal Anti-Inflammatory Drugs
11.2.1.1.1.1 Ibuprofen
11.2.1.1.1.2 Naproxen
11.2.1.1.1.3 Celecoxib
11.2.1.1.1.4 Mefenamic Acid
11.2.1.1.1.5 Meclofenamate
11.2.1.1.2 Acetaminophen
11.2.1.2 Hormonal Replacement Therapy y
11.2.1.2.1 Combined Oral Contraceptives (Monophasic or Multiphasic)
11.2.1.2.1.1 Norethindrone/Ethinyl Estradiol
11.2.1.2.1.2 Extended-Cycle Oral Contraceptives
11.2.1.2.2 Extended-Cycle Oral Contraceptives
11.2.1.2.2.1 Levonorgestrel/Ethinyl Estradiol
11.2.1.2.2.2 Others
11.2.1.2.3 Other
11.2.1.2.3.1 Etonogestrel/Ethinyl Estradiol
11.2.1.2.3.2 Etonogestrel Implant
11.2.1.2.3.3 Levonorgestrel-Releasing Intrauterine System
11.2.1.2.3.4 Medroxyprogesterone Shot
11.2.1.3 Diuretic
11.2.1.3.1 Spironolactone
11.2.1.3.2 Ammonium Chloride
11.2.1.4 Antidepressants
11.2.2 SECOND LINE TREATMENT
11.2.2.1 Empiric GNRH Analogue or Antagonist Therapy
11.2.2.2 Ammonium Chloride
11.3 THERAPY
11.3.1 HEAT THERAPY
11.3.1.1 Patch
11.3.1.2 Wrap
11.3.1.3 Ceramic Belt Emitting Far-Infrared Radiation (FIR)
11.3.2 BEHAVIORAL COUNSELING
11.3.2.1 Desensitization-Based Procedures
11.3.2.2 Coping Strategies
11.3.2.3 Imagery
11.3.2.4 Hypnotherapy
11.3.2.5 Others
11.3.3 DIET AND VITAMINS
11.3.3.1 Vitamin E
11.3.3.2 Vitamin B
11.3.3.3 Vitamin D
11.3.3.4 Others
11.4 SURGERY
11.4.1 ENDOMETRIAL ABLATION
11.4.2 HYSTERECTOMY
11.5 OTHERS
12 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION
12.1 OVERVIEW
12.2 OVER THE COUNTER
12.3 PRESCRIPTION
13 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
13.1 OVERVIEW
13.2 ORAL
13.2.1 TABLETS
13.2.2 PILLS
13.2.3 CAPSULE
13.2.4 OTHERS
13.3 PARENTERAL
13.3.1 INTRAVENOUS
13.3.2 SUBCUTANEOUS
13.3.3 OTHERS
13.4 IMPLANTS
13.5 OTHERS
14 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITALS
14.3 SPECIALTY CENTERS
14.4 AMBULATORY SURGICAL CENTERS
14.5 OTHERS
15 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 PHARMACIES
15.2.1 HOSPITAL
15.2.2 RETAIL
15.3 DIRECT TENDER
15.4 RETAIL SALES
15.5 OTHERS
16 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY GEOGRAPHY
16.1 NORTH AMERICA
16.1.1 U.S
16.1.2 CANADA
16.1.3 MEXICO
17 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
18 SWOT ANALYSIS
19 COMPANY PROFILE
19.1 GLAXOSMITHKLINE PLC.
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 COMPANY SHARE ANALYSIS
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENTS
19.2 JANSSEN PHARMACEUTICALS, INC. (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.)
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 COMPANY SHARE ANALYSIS
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPMENT
19.3 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.)
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUE ANALYSIS
19.3.3 COMPANY SHARE ANLYSIS
19.3.4 PRODUCT PORTFOLIO
19.3.5 RECENT DEVELOPMENTS
19.4 ABBVIE INC.
19.4.1 COMPANY SNAPSHOT
19.4.2 REVENUE ANALYSIS
19.4.3 COMPANY SHARE ANALYSIS
19.4.4 PRODUCT PORTFOLIO
19.4.5 RECENT DEVELOPMENTS
19.5 MYLAN N. V. (A PART OF VIATRIS INC.).
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 PRODUCT PORTFOLIO
19.5.4 RECENT DEVELOPMENT
19.6 ALVOGEN
19.6.1 COMPANY SNAPSHOT
19.6.2 PRODUCT PORTFOLIO
19.6.3 RECENT DEVELOPMENT
19.7 BAYER AG
19.7.1 COMPANY SNAPSHOT
19.7.2 REVENUE ANALYSIS
19.7.3 PRODUCT PORTFOLIO
19.7.4 RECENT DEVELOPMENTS
19.8 BEURER GMBH
19.8.1 COMPANY SNAPSHOT
19.8.2 PRODUCT PORTFOLIO
19.8.3 RECENT DEVELOPMENT
19.9 BIOELECTRONICS CORPORATION
19.9.1 COMPANY SNAPSHOT
19.9.2 REVENUE ANALYSIS
19.9.3 PRODUCT PORTFOLIO
19.9.4 RECENT DEVELOPMENT
19.1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
19.10.1 COMPANY SNAPSHOT
19.10.2 REVENUE ANALYSIS
19.10.3 PRODUCT PORTFOLIO
19.10.4 RECENT DEVELOPMENT
19.11 COLOR SEVEN CO., LTD.
19.11.1 COMPANY SNAPSHOT
19.11.2 PRODUCT PORTFOLIO
19.11.3 RECENT DEVELOPMENTS
19.12 CUMBERLAND PHARMACEUTICALS INC.
19.12.1 COMPANY SNAPSHOT
19.12.2 REVENUE ANALYSIS
19.12.3 PRODUCT PORTFOLIO
19.12.4 RECENT DEVELOPMENTS
19.13 LIVIA
19.13.1 COMPANY SNAPSHOT
19.13.2 PRODUCT PORTFOLIO
19.13.3 RECENT DEVELOPMENTS
19.14 LUPIN PHARMACEUTICALS, INC. (A SUBSIDIARY OF LUPIN)
19.14.1 COMPANY SNAPSHOT
19.14.2 REVENUE ANALYSIS
19.14.3 PRODUCT PORTFOLIO
19.14.4 RECENT DEVELOPMENTS
19.15 MYOVANT SCIENCES LTD.
19.15.1 COMPANY SNAPSHOT
19.15.2 PRODUCT PORTFOLIO
19.15.3 RECENT DEVELOPMENT
19.16 NOBELPHARMA CO., LTD.
19.16.1 COMPANY SNAPSHOT
19.16.2 REVENUE ANALYSIS
19.16.3 PRODUCT PORTFOLIO
19.16.4 RECENT DEVELOPMENT
19.17 OBSEVA
19.17.1 COMPANY SNAPSHOT
19.17.2 PRODUCT PORTFOLIO
19.17.3 RECENT DEVELOPMENTS
19.18 PFIZER INC.
19.18.1 COMPANY SNAPSHOT
19.18.2 REVENUE ANALYSIS
19.18.3 PRODUCT PORTFOLIO
19.18.4 RECENT DEVELOPMENTS
19.19 PMS4PMS, LLC
19.19.1 COMPANY SNAPSHOT
19.19.2 PRODUCT PORTFOLIO
19.19.3 RECENT DEVELOPMENT
19.2 SANOFI
19.20.1 COMPANY SNAPSHOT
19.20.2 REVENUE ANALYSIS
19.20.3 PRODUCT PORTFOLIO
19.20.4 RECENT DEVELOPMENT
19.21 SUN PHARMACEUTICAL INDUSTRIES LTD.
19.21.1 COMPANY SNAPSHOT
19.21.2 REVENUE ANALYSIS
19.21.3 PRODUCT PORTFOLIO
19.21.4 RECENT DEVELOPMENT
20 QUESTIONNAIRE
21 RELATED REPORTS
Lista de Tabela
LIST OF TABLES
TABLE 1 MARKETING EXPENSES OF THE MARKET PLAYERS
TABLE 2 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 3 NORTH AMERICA PRIMARY DYSMENORRHEA IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 4 NORTH AMERICA SECONDARY DYSMENORRHEA IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 5 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 6 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)
TABLE 7 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)
TABLE 8 NORTH AMERICA MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 9 NORTH AMERICA MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 10 NORTH AMERICA FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 11 NORTH AMERICA NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 12 NORTH AMERICA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 13 NORTH AMERICA HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 14 NORTH AMERICA COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 15 NORTH AMERICA EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 16 NORTH AMERICA OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 17 NORTH AMERICA DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 18 NORTH AMERICA SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 19 NORTH AMERICA THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 20 NORTH AMERICA THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 21 NORTH AMERICA HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 22 NORTH AMERICA BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 23 NORTH AMERICA DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 24 NORTH AMERICA SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 25 NORTH AMERICA SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 26 NORTH AMERICA OTHERS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 27 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)
TABLE 28 NORTH AMERICA OVER THE COUNTER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 29 NORTH AMERICA PRESCRIPTION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 30 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 31 NORTH AMERICA ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 32 NORTH AMERICA ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 33 NORTH AMERICA PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 34 NORTH AMERICA PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 35 NORTH AMERICA IMPLANTS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 36 NORTH AMERICA OTHERS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 37 NORTH AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2020-2028 (USD MILLION)
TABLE 38 NORTH AMERICA HOSPITALS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 39 NORTH AMERICA SPECIALTY CENTERS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 40 NORTH AMERICA AMBULATORY SURGICAL CENTERS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 41 NORTH AMERICA OTHERS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 42 NORTH AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)
TABLE 43 NORTH AMERICA PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 44 NORTH AMERICA PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 45 NORTH AMERICA DIRECT TENDER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 46 NORTH AMERICA RETAIL SALES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 47 NORTH AMERICA OTHERS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 48 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 49 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 50 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 51 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)
TABLE 52 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)
TABLE 53 NORTH AMERICA MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 54 NORTH AMERICA FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 55 NORTH AMERICA NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 56 NORTH AMERICA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 57 NORTH AMERICA HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 58 NORTH AMERICA COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 59 NORTH AMERICA EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 60 NORTH AMERICA OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 61 NORTH AMERICA DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 62 NORTH AMERICA SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 63 NORTH AMERICA THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 64 NORTH AMERICA HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 65 NORTH AMERICA BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 66 NORTH AMERICA DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 67 NORTH AMERICA SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 68 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)
TABLE 69 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 70 NORTH AMERICA ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 71 NORTH AMERICA PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 72 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 73 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 74 NORTH AMERICA PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 75 U.S. MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 76 U.S. MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 77 U.S. MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)
TABLE 78 U.S. MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)
TABLE 79 U.S. MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 80 U.S. FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 81 U.S. NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 82 U.S. NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 83 U.S. HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 84 U.S. COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 85 U.S. EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 86 U.S. OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 87 U.S. DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 88 U.S. SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 89 U.S. THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 90 U.S. HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 91 U.S. BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 92 U.S. DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 93 U.S. SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 94 U.S. MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)
TABLE 95 U.S. MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 96 U.S. ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 97 U.S. PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 98 U.S. MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 99 U.S. MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 100 U.S. PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 101 CANADA MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 102 CANADA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 103 CANADA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)
TABLE 104 CANADA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)
TABLE 105 CANADA MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 106 CANADA FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 107 CANADA NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 108 CANADA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 109 CANADA HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 110 CANADA COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 111 CANADA EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 112 CANADA OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 113 CANADA DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 114 CANADA SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 115 CANADA THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 116 CANADA HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 117 CANADA BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 118 CANADA DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 119 CANADA SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 120 CANADA MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)
TABLE 121 CANADA MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 122 CANADA ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 123 CANADA PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 124 CANADA MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 125 CANADA MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 126 CANADA PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 127 MEXICO MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 128 MEXICO MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 129 MEXICO MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)
TABLE 130 MEXICO MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)
TABLE 131 MEXICO MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 132 MEXICO FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 133 MEXICO NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 134 MEXICO NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 135 MEXICO HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 136 MEXICO COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 137 MEXICO EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 138 MEXICO OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 139 MEXICO DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 140 MEXICO SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 141 MEXICO THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 142 MEXICO HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 143 MEXICO BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 144 MEXICO DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 145 MEXICO SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 146 MEXICO MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)
TABLE 147 MEXICO MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 148 MEXICO ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 149 MEXICO PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 150 MEXICO MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 151 MEXICO MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 152 MEXICO PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
Lista de Figura
LIST OF FIGURES
FIGURE 1 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 8 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 NORTH AMERICA IS ANTICIPATED TO DOMINATE THE NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET AND ASIA-PACIFIC IS ESTIMATED TO BE GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 10 INCREASING PREVALENCE OF DYSMENORRHEA IS EXPECTED TO DRIVE THE NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 11 PRIMARY DYSMENORRHEA SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET IN 2021 & 2028
FIGURE 12 PHARMACIES COLD/HOT PADS MARKET SHARE: 2020 (%)
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET
FIGURE 14 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY TYPE, 2020
FIGURE 15 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY TYPE, 2020-2028 (USD MILLION)
FIGURE 16 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY TYPE, CAGR (2021-2028)
FIGURE 17 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY TYPE, LIFELINE CURVE
FIGURE 18 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY TREATMENT TYPE, 2020
FIGURE 19 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY TREATMENT TYPE, 2020-2028 (USD MILLION)
FIGURE 20 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY TREATMENT TYPE, CAGR (2021-2028)
FIGURE 21 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY TREATMENT TYPE, LIFELINE CURVE
FIGURE 22 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY MODE OF PRESCRIPTION, 2020
FIGURE 23 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY MODE OF PRESCRIPTION 2020-2028 (USD MILLION)
FIGURE 24 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY MODE OF PRESCRIPTION, CAGR (2021-2028)
FIGURE 25 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY MODE OF PRESCRIPTION, LIFELINE CURVE
FIGURE 26 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020
FIGURE 27 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020-2028 (USD MILLION)
FIGURE 28 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2021-2028)
FIGURE 29 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 30 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY END USER, 2020
FIGURE 31 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY END USER, 2020-2028 (USD MILLION)
FIGURE 32 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY END USER, CAGR (2021-2028)
FIGURE 33 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 34 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 35 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)
FIGURE 36 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 37 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 38 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: SNAPSHOT (2020)
FIGURE 39 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY COUNTRY (2020)
FIGURE 40 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY COUNTRY (2021 & 2028)
FIGURE 41 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY COUNTRY (2020 & 2028)
FIGURE 42 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY TYPE (2021-2028)
FIGURE 43 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: COMPANY SHARE 2020 (%)
Metodologia de Investigação
A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.
A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.
Personalização disponível
A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.
